These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 30087114)

  • 1. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in
    Adeegbe DO; Liu S; Hattersley MM; Bowden M; Zhou CW; Li S; Vlahos R; Grondine M; Dolgalev I; Ivanova EV; Quinn MM; Gao P; Hammerman PS; Bradner JE; Diehl JA; Rustgi AK; Bass AJ; Tsirigos A; Freeman GJ; Chen H; Wong KK
    Cancer Immunol Res; 2018 Oct; 6(10):1234-1245. PubMed ID: 30087114
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
    Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK
    J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Predictive Value of
    Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
    Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
    [No Abstract]   [Full Text] [Related]  

  • 9. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
    Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
    Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic
    Meraz IM; Majidi M; Cao X; Lin H; Li L; Wang J; Baladandayuthapani V; Rice D; Sepesi B; Ji L; Roth JA
    Cancer Immunol Res; 2018 Feb; 6(2):163-177. PubMed ID: 29339375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer.
    Ritzmann F; Jungnickel C; Vella G; Kamyschnikow A; Herr C; Li D; Menger MM; Angenendt A; Hoth M; Lis A; Bals R; Beisswenger C
    Sci Rep; 2019 Jul; 9(1):10353. PubMed ID: 31316109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
    Aredo JV; Padda SK; Kunder CA; Han SS; Neal JW; Shrager JB; Wakelee HA
    Lung Cancer; 2019 Jul; 133():144-150. PubMed ID: 31200821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
    Bouillez A; Rajabi H; Pitroda S; Jin C; Alam M; Kharbanda A; Tagde A; Wong KK; Kufe D
    Cancer Res; 2016 Mar; 76(6):1538-48. PubMed ID: 26833129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
    Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
    Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
    Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
    Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.